Clinical trial

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

NCT05458674

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2024-01-30

PhasePHASE2

Study timeline

Study start (actual)2024-01-30Date precision: day

Registry last updated2026-07-10

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancerunresolved

Interventions

TucatinibDRUG · verified · RxNorm: tucatinib

EribulinDRUG · verified · RxNorm: eribulin

TrastuzumabDRUG · verified · RxNorm: trastuzumab

Sponsors & collaborators

Criterium, Inc.lead sponsor

Mapped research locations

Washington D.C.District of Columbia, United States1 AuroraColorado, United States1 AlbuquerqueNew Mexico, United States1 MadisonWisconsin, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05458674 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.